Orgaansparende behandeling bij slokdarmcarcinoom: HAALBAAR EN VERANTWOORD?

Translated title of the contribution: Organ-sparing treatment in oesophagus cancer: Feasible and safe?

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

In many countries, neoadjuvant chemoradiotherapy (nCRT) plus surgery is standard treatment for resectable oesophageal cancer. After nCRT, up to 30% of all patients have no residual disease in the resection specimen. Consequently, an active surveillance approach, in which patients undergo frequent clinical investigations after nCRT instead of standard oesophagectomy, is increasingly applied in selected patients. Here, we describe outcomes for three patients who underwent active surveillance. A 63-year old woman was considered unfit for surgery after nCRT. Four years after completion of nCRT, she still had no signs of disease recurrence. The second patient, a 57-year old woman, refused surgery when no residual disease was detectable after nCRT. One year following treatment, she developed a vertebral metastasis, in the absence of locoregional disease. The third patient concerned a 66-year old man with a clinically complete response after nCRT, who also refused surgery. During active surveillance, he developed a locoregional regrowth and underwent a radical oesophagectomy.

Translated title of the contributionOrgan-sparing treatment in oesophagus cancer: Feasible and safe?
Original languageDutch
Number of pages6
JournalNederlands Tijdschrift voor Geneeskunde
Volume161
Issue number45
Publication statusPublished - 2017

Fingerprint

Dive into the research topics of 'Organ-sparing treatment in oesophagus cancer: Feasible and safe?'. Together they form a unique fingerprint.

Cite this